Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective

Published:2016-05-03 Issue:6 Volume:26 Page:e12505
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care

Author:

Zheng H.R.¹,Wen F.²,Wu Y.F.³,Wheeler J.R.C.³,Li Q.²

Affiliation:

1. Department of Clinical Pharmacy; West China Hospital; Sichuan University; Sichuan China

2. Department of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Sichuan China

3. School of Public Health; University of Michigan; Ann Arbor MI USA

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12505/fullpdf

Reference25 articles.

1. International variation in prostate cancer incidence and mortality rates;Center;European Urology,2012

2. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?;Eichler;Value Health,2004

3. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale;Elbasha;Health Economics,2004

4. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer;Fitzpatrick;European Urology,2014

5. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and Contra;Fizazi;Annals of Oncology,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective;Value in Health Regional Issues;2024-07

2. Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations;Clinical Genitourinary Cancer;2022-12

3. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer;PLOS ONE;2022-11-03

4. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context;Current Oncology;2022-05-07

5. A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer;Expert Opinion on Pharmacotherapy;2021-06-02